Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.

By Deepak L. Bhatt, K. Fox, W. Hacke, P. Berger, H. Black, W. Boden, P. Cacoub, E. Cohen, M. Creager, J. Easton and 16 more. New England Journal of Medicine, 2006

2,546 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine

View Paper: https://www.semanticscholar.org/paper/8e9360f62ea548189c4ec9407d8f38d41f58152d

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

Citations in the corpus

2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2008, methodology): “On the basis of the criteria/considerations noted above, recent trial data and other clinical information were considered important enough to prompt a focused update of the 2004 ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction [see Chen ZM et al. (3); Chen ZM”
2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “aspirin alone was tested in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilisation, Management, and Avoidance (CHARISMA) trial and was not of significant benefit.(471) The results of the four major ongoing primary prevention trials—two in DM patients,(472,473) one in individuals o”
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, positive): “However, in The Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial of patients with established atherosclerosis or multiple risk factors for atherosclerosis, the addition of clopidogrel to aspirin was no more effective than aspirin alone”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2016, background): “aspirin alone was tested in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilisation, Management, and Avoidance (CHARISMA) trial and was not of significant benefit.(471) The results of the four major ongoing primary prevention trials—two in DM patients,(472,473) one in individuals o”
Stroke Risk Factors, Genetics, and Prevention (2017, background): “There is no convincing evidence for the use of dual antiplatelet therapies, such as aspirin and clopidogrel combined, for primary stroke prevention.(261) In the CHARISMA trial (Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events), for example, 15 603 patients w”
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. (2007, methodology): “In a prespecied analysis of the CHARISMA trial, the 12,153 patients nrolled with established disease (documented cardiovascuar, cerebrovascular, or peripheral arterial disease [PAD]) eemed to derive a significant benefit from combination herapy, while the 3,284 patients without documented isease but”